Cargando…

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings

BACKGROUND: The use of antibiotics is known to alter the gut microbiome and it is hypothesised that the use of antibiotics may also alter the response to immune checkpoint inhibitors (ICI). As data is limited from real-world settings, we performed a retrospective audit of patients who received ICI a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Akhil, Noronha, Vanita, Patil, Vijay M, Joshi, Amit, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289608/
https://www.ncbi.nlm.nih.gov/pubmed/32565891
http://dx.doi.org/10.3332/ecancer.2020.1038
_version_ 1783545496894177280
author Kapoor, Akhil
Noronha, Vanita
Patil, Vijay M
Joshi, Amit
Menon, Nandini
Mahajan, Abhishek
Janu, Amit
Prabhash, Kumar
author_facet Kapoor, Akhil
Noronha, Vanita
Patil, Vijay M
Joshi, Amit
Menon, Nandini
Mahajan, Abhishek
Janu, Amit
Prabhash, Kumar
author_sort Kapoor, Akhil
collection PubMed
description BACKGROUND: The use of antibiotics is known to alter the gut microbiome and it is hypothesised that the use of antibiotics may also alter the response to immune checkpoint inhibitors (ICI). As data is limited from real-world settings, we performed a retrospective audit of patients who received ICI along with concomitant antibiotics. PATIENTS AND METHODS: This study is a retrospective audit of a prospectively collected the database of patients who received ICI for advanced solid tumours in any line between August 2015 and November 2018 at Tata Memorial Hospital, Mumbai, India. Antibiotic use was recorded from 2 weeks before the start of ICI and concomitantly with ICI. All statistical calculations were performed using Statistical Package for the Social Sciences (SPSS) statistical software for windows version 20.0. RESULTS: A total of 155 patients were identified as having received ICI during the study period, out of which 70 (44%) patients received antibiotics. Median PFS in patients who received antibiotics was 1.7 months (95% CI: 1.1–2.3) as against 3.6 months (95% CI: 2.3–4.8) for patients who did not receive antibiotics (p = 0.912). Median OS in the patients who received antibiotics was 3.9 months (95% CI: 1.8–11.4) as compared to 9.2 months (95% CI: 4.2–12.3) who did not receive antibiotics p = 0.053 (HR = 1.023; 95% CI: 1.00–1.04). Among the patients who received antibiotics, median OS for patients who received ≤10 days of antibiotics was 8.8 months (95% CI: 4.2–11.2) while for patients receiving >10 days of antibiotics, it was 2.8 months (95% CI: 1.2–4.4), p = 0.025 (HR = 2.0, 95% CI: 1.1–3.7). Thirty-three (21.2% of total) patients received antibiotics during the window of 2 weeks before the start of ICI to 2 months of starting ICI. Median OS in the patients who received antibiotics in this window was 2.8 months (95% CI: 1.2–4.5) as compared to 9.2 months (95% CI: 5.2–13.1) who did not receive antibiotics p = 0.008 (HR = 1.8; 95%CI: 1.2–3.0). CONCLUSIONS: This study shows that the judicious use of antibiotics is required in patients on ICI or scheduled to be started on ICI.
format Online
Article
Text
id pubmed-7289608
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-72896082020-06-19 Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings Kapoor, Akhil Noronha, Vanita Patil, Vijay M Joshi, Amit Menon, Nandini Mahajan, Abhishek Janu, Amit Prabhash, Kumar Ecancermedicalscience Clinical Study BACKGROUND: The use of antibiotics is known to alter the gut microbiome and it is hypothesised that the use of antibiotics may also alter the response to immune checkpoint inhibitors (ICI). As data is limited from real-world settings, we performed a retrospective audit of patients who received ICI along with concomitant antibiotics. PATIENTS AND METHODS: This study is a retrospective audit of a prospectively collected the database of patients who received ICI for advanced solid tumours in any line between August 2015 and November 2018 at Tata Memorial Hospital, Mumbai, India. Antibiotic use was recorded from 2 weeks before the start of ICI and concomitantly with ICI. All statistical calculations were performed using Statistical Package for the Social Sciences (SPSS) statistical software for windows version 20.0. RESULTS: A total of 155 patients were identified as having received ICI during the study period, out of which 70 (44%) patients received antibiotics. Median PFS in patients who received antibiotics was 1.7 months (95% CI: 1.1–2.3) as against 3.6 months (95% CI: 2.3–4.8) for patients who did not receive antibiotics (p = 0.912). Median OS in the patients who received antibiotics was 3.9 months (95% CI: 1.8–11.4) as compared to 9.2 months (95% CI: 4.2–12.3) who did not receive antibiotics p = 0.053 (HR = 1.023; 95% CI: 1.00–1.04). Among the patients who received antibiotics, median OS for patients who received ≤10 days of antibiotics was 8.8 months (95% CI: 4.2–11.2) while for patients receiving >10 days of antibiotics, it was 2.8 months (95% CI: 1.2–4.4), p = 0.025 (HR = 2.0, 95% CI: 1.1–3.7). Thirty-three (21.2% of total) patients received antibiotics during the window of 2 weeks before the start of ICI to 2 months of starting ICI. Median OS in the patients who received antibiotics in this window was 2.8 months (95% CI: 1.2–4.5) as compared to 9.2 months (95% CI: 5.2–13.1) who did not receive antibiotics p = 0.008 (HR = 1.8; 95%CI: 1.2–3.0). CONCLUSIONS: This study shows that the judicious use of antibiotics is required in patients on ICI or scheduled to be started on ICI. Cancer Intelligence 2020-05-08 /pmc/articles/PMC7289608/ /pubmed/32565891 http://dx.doi.org/10.3332/ecancer.2020.1038 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Kapoor, Akhil
Noronha, Vanita
Patil, Vijay M
Joshi, Amit
Menon, Nandini
Mahajan, Abhishek
Janu, Amit
Prabhash, Kumar
Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
title Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
title_full Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
title_fullStr Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
title_full_unstemmed Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
title_short Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
title_sort concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289608/
https://www.ncbi.nlm.nih.gov/pubmed/32565891
http://dx.doi.org/10.3332/ecancer.2020.1038
work_keys_str_mv AT kapoorakhil concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT noronhavanita concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT patilvijaym concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT joshiamit concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT menonnandini concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT mahajanabhishek concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT januamit concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings
AT prabhashkumar concomitantuseofantibioticsandimmunecheckpointinhibitorsinpatientswithsolidneoplasmsretrospectivedatafromrealworldsettings